CD105 expression is an independent predictor of survival in patients with endometrial cancer

Erdem O., Taskiran C., Onan M. A., Erdem M., Guner H., Ataoglu O.

GYNECOLOGIC ONCOLOGY, cilt.103, sa.3, ss.1007-1011, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 103 Sayı: 3
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1016/j.ygyno.2006.06.010
  • Dergi Adı: GYNECOLOGIC ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1007-1011
  • Anahtar Kelimeler: angiogenesis, CD105, CD34, VEGF, endometrial cancer, survival, ENDOTHELIAL GROWTH-FACTOR, TUMOR ANGIOGENESIS, BREAST-CARCINOMA, PROGNOSTIC INDICATOR, ENDOGLIN CD105, CELL MARKERS, VASCULATURE, HYPERPLASIA, CD34
  • Gazi Üniversitesi Adresli: Evet

Özet

Objective. The purpose of this study was to detect the prognostic value of CD105 (endoglin) and also to compare with CD34 and vascular endothelial growth factor (VEGF) in patients with endometrial adenocancer.